PURPOSE: The purpose of the present study was to assess the long-term success rate of a single 3-min freeze per vein ablation strategy in the setting of pulmonary vein isolation (PVI) by means of second-generation cryoballoon (CB-A; Arctic Front Advance, Medtronic, Minneapolis, MN, USA) in a large cohort of patients. METHODS: Three hundred and one patients with drug resistant atrial fibrillation (AF) having undergone PVI by means of CB-A using a single 3-min freeze per vein ablation strategy were included in the analysis. RESULTS: Paroxysmal AF (PAF) was documented in 70.8% of the patients, while 29.2% presented with persistent AF (PersAF). The mean number of CB applications was 1.09 ± 0.3 in the left superior pulmonary vein (LSPV), 1.04 ± 0.2 in the left inferior pulmonary vein (LIPV), 1.12 ± 0.3 in the right superior pulmonary vein (RSPV), and 1.12 ± 0.3 in the right inferior pulmonary vein (RIPV). All PVs were successfully isolated with a 28-mm CB-A only. After a mean follow-up of 38.1 ± 7.5 months, 207 (68.8%) patients were free of atrial tachyarrhythmia (ATa) recurrences following a single procedure. Specifically, 72.8% of patients presenting with PAF and 59.1% of individuals with PersAF did not experience a recurrence. CONCLUSIONS: A single 3-min freeze per vein strategy is effective in treating AF on a long term follow-up of 38 months. Specifically, it can afford freedom from ATa recurrences in 72.8% of patients affected by PAF and 59.1% of patients initially presenting with PersAF after a single CB-A procedure.
PURPOSE: The purpose of the present study was to assess the long-term success rate of a single 3-min freeze per vein ablation strategy in the setting of pulmonary vein isolation (PVI) by means of second-generation cryoballoon (CB-A; Arctic Front Advance, Medtronic, Minneapolis, MN, USA) in a large cohort of patients. METHODS: Three hundred and one patients with drug resistant atrial fibrillation (AF) having undergone PVI by means of CB-A using a single 3-min freeze per vein ablation strategy were included in the analysis. RESULTS: Paroxysmal AF (PAF) was documented in 70.8% of the patients, while 29.2% presented with persistent AF (PersAF). The mean number of CB applications was 1.09 ± 0.3 in the left superior pulmonary vein (LSPV), 1.04 ± 0.2 in the left inferior pulmonary vein (LIPV), 1.12 ± 0.3 in the right superior pulmonary vein (RSPV), and 1.12 ± 0.3 in the right inferior pulmonary vein (RIPV). All PVs were successfully isolated with a 28-mm CB-A only. After a mean follow-up of 38.1 ± 7.5 months, 207 (68.8%) patients were free of atrial tachyarrhythmia (ATa) recurrences following a single procedure. Specifically, 72.8% of patients presenting with PAF and 59.1% of individuals with PersAF did not experience a recurrence. CONCLUSIONS: A single 3-min freeze per vein strategy is effective in treating AF on a long term follow-up of 38 months. Specifically, it can afford freedom from ATa recurrences in 72.8% of patients affected by PAF and 59.1% of patients initially presenting with PersAF after a single CB-A procedure.
Authors: Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; Jose Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber Journal: J Interv Card Electrophysiol Date: 2012-03 Impact factor: 1.900
Authors: Giacomo Mugnai; Carlo de Asmundis; Burak Hünük; Erwin Ströker; Vedran Velagic; Darragh Moran; Diego Ruggiero; Ebru Hacioglu; Jan Poelaert; Christian Verborgh; Vincent Umbrain; Stefan Beckers; Hugo Enrique Coutino-Moreno; Ken Takarada; Pedro Brugada; Gian-Battista Chierchia Journal: Heart Rhythm Date: 2015-12-24 Impact factor: 6.343
Authors: Erik Wissner; Christian-Hendrik Heeger; Hanno Grahn; Bruno Reissmann; Peter Wohlmuth; Christine Lemes; Peter Rausch; Shibu Mathew; Andreas Rillig; Sebastian Deiss; Tillman Maurer; Tina Lin; Roland Richard Tilz; Feifan Ouyang; Karl-Heinz Kuck; Andreas Metzner Journal: Europace Date: 2015-04-12 Impact factor: 5.214
Authors: Jayakeerthi Yoganarasimha Rao; Gian-Battista Chierchia; Carlo de Asmundis; Ruben Casado-Arroyo; Ingrid Overeinder; Andrea Sarkozy; Gaetano Paparella; Lucio Capulzini; Antonio Sorgente; Moises Rodriguez-Manero; Danilo Ricciardi; Mehdi Namdar; Pedro Brugada Journal: J Cardiovasc Med (Hagerstown) Date: 2014-03 Impact factor: 2.160
Authors: Waqas Ullah; Liang-Han Ling; Sandeep Prabhu; Geoffrey Lee; Peter Kistler; Malcolm C Finlay; Mark J Earley; Simon Sporton; Yaver Bashir; Tim R Betts; Kim Rajappan; Glyn Thomas; Edward Duncan; Andrew Staniforth; Ian Mann; Anthony Chow; Pier Lambiase; Richard J Schilling; Ross J Hunter Journal: Europace Date: 2016-02-03 Impact factor: 5.214
Authors: Saverio Iacopino; Gaetano Paparella; Lucio Capulzini; Erwin Ströker; Stefan Beckers; Thiago Guimarães Osório; Varnavas Varnavas; Juan Sieira; Juan Pablo Abugattas; Riccardo Maj; Francesca Salghetti; Vincent Umbrain; Muryo Terasawa; Pedro Brugada; Carlo de Asmundis; Gian Battista Chierchia Journal: J Interv Card Electrophysiol Date: 2019-04-27 Impact factor: 1.900